Company profile: ECM Therapeutics
1.1 - Company Overview
Company description
- Provider of regenerative natural biomaterials, including extracellular matrix hydrogel for tissue regeneration, void filling, and as a drug carrier; matrix bound nanovesicles offering immunomodulation without suppression, administered intravenously or topically; and FDA-approved extracellular matrix-based surgical scaffolds for applications such as hernia repair and breast reconstruction.
Products and services
- Biologic Scaffolds: FDA-approved, extracellular matrix–derived surgical mesh materials constructed for applications including hernia repair and breast reconstruction
- Extracellular Matrix Hydrogel: ECM-derived hydrogel produced for delivering tissue-regenerating properties to various body parts, potentially used for void filling and as a drug carrier
- Matrix Bound Nanovesicles (MBV): Matrix-bound biotherapeutic platform architected for immunomodulation without suppression, administered in various forms including intravenously and topically
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ECM Therapeutics
ImaginAb
HQ: United States
Website
- Description: Provider of molecular imaging solutions for cancer and autoimmune disease management by re-engineering antibodies into small proteins. Offers non-invasive CD8 ImmunoPET to visualize CD8-positive T cells across the body and assess treatment effectiveness, develops therapeutic radiopharmaceuticals using antibody fragment platforms, and supports clinical trials through CD8 ImmunoPET implementation and partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImaginAb company profile →
Mainz Biomed
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic solutions for early cancer detection, including ColoAlert, a non-invasive at-home PCR-based colorectal cancer screening test; eAArly DETECT, a multimodal test combining FIT, mRNA biomarkers and AI to differentiate CRC, advanced and non-advanced adenomas; PancAlert, an early-stage pancreatic cancer screening test in development; and ReconAAsense, an FDA PMA pivotal study for next-gen colorectal screening approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mainz Biomed company profile →
RainDance Technologies
HQ: United States
Website
- Description: Provider of medical technology solutions leveraging droplet technology for research in areas including non-invasive liquid biopsy, and offering molecules, single-cell analyses, reaction methodology, cancer research, mutation detection, and diagnostics services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RainDance Technologies company profile →
Pharmacyclics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmacyclics company profile →
Spotlight Therapeutics
HQ: United States
Website
- Description: Provider of targeted biologic gene editing solutions, including Targeted Active Gene Editors (cell-targeted CRISPR-Cas ribonucleoproteins) for non-viral in vivo delivery in immuno-oncology and genetic diseases; localized eRNP editing for retinal cells via subretinal delivery; eRNP applications in the CNS; and a high-throughput screen to identify Cas fusion proteins for selective internalization and localization in primary cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spotlight Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ECM Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ECM Therapeutics
2.2 - Growth funds investing in similar companies to ECM Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ECM Therapeutics
4.2 - Public trading comparable groups for ECM Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →